Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899779 | 0.89 | KDM1A (0.44) | KDM1ACES2CES1KDM1B | |
| SCHEMBL5899780 | 0.82 | KDM1A (0.47) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL5899781 | 0.80 | HTR2C (0.42) | HTR2CHTR2BKDM1ACES2CES1 | |
| SCHEMBL5899774 | 0.80 | KDM1A (0.49) | HTR2AHTR2CHTR2BKDM1AGRIN2B | |
| SCHEMBL5899615 | 0.79 | KDM1A (0.44) | HTR2AHTR2CHTR2BKDM1ASLC6A2 | |
| SCHEMBL5899701 | 0.78 | HTR2C (0.38) | HTR2CHTR2BKDM1ACES2CES1 | |
| SCHEMBL5899782 | 0.76 | TUBB4A (0.32) | KDM1ACES2CES1 | |
| SCHEMBL5899791 | 0.75 | TRPA1 (0.40) | HTR2AHTR2CGRIN2BLTB4RLTB4R2 | |
| SCHEMBL5899756 | 0.73 | HTR2A (0.41) | HTR2AHTR2CGRIN2B | |
| SCHEMBL28520686 | 0.73 | OPRL1 (0.43) | HTR2AHTR2CHTR2BOPRL1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | HTR2A 235/4885HTR2C 285/4885HTR2B 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.